Takeda Pharmaceutical Company Limited

Takeda Pharmaceuticals, Japan, one of the world's largest pharmaceutical companies, is going to invest RUB 2.3 billion in expanding the production of medicines at its factory in the Yaroslavl Region. The agreement was signed on Thursday at the St. Petersburg International Economic Forum 2021 by Dmitry Mironov, the Region’s Governor, and Chris Buttkus, Director of Takeda Russia factory in Yaroslavl, the company's press office said.

03 June 2021

The Japanese company Takeda today, April 23, launched a production line for Ninlaro drug at the Yaroslavl plant, which is designed for the treatment of severe cancer cases - multiple myeloma.

23 April 2021

Takeda completed the localization of the production of Advate (Octocog alpha) medicine, intended for the treatment of patients with hemophilia A, at the Moscow-based Biocad plant. This was told to Kommersant in the Japanese company. They explained that the parties had organized the release of the finished dosage form of the medicine, as well as the primary packaging. The parties do not disclose the amount of investments in the localization.

03 April 2019

Japanese pharmaceutical company Takeda invested over 98 million euros in the production of pharmaceuticals in Russia, 477 million rubles of which were assigned to the production of innovation orphan drug Ixazomib named Ninlaro for patients with multiple myeloma (blood cancer). This information was provided to TASS by a company’s press service representative at the opening ceremony of the drug manufacturing site of the plant in Yaroslavl.

01 August 2018

International pharmaceutical company Takeda announces launching the production of innovation drug Ixazomib for patients with multiple myeloma (blood cancer) at its plant in Yaroslavl. The official start-up is scheduled for the 1-st of August.

25 July 2018

Takeda Pharmaceutical and Pharmstandard, JSC started cooperation on localizing the production of the onco-hematological drug Adcetris (brentuximab vedotin) at the Ufa-based plant.

10 October 2017

Takeda has launched its integrated production of Actovegin in the form of sterile injection solution at its Yaroslavl plant. Thus all forms of the drug (pills and injections solutions) are now produced in Russia.

27 September 2016

Japan’s Takeda Pharmaceutical Company is not ruling out the possibility of acquisitions in Russia, Takeda President and Representative Director Christophe Weber told Vedomosti. He noted that the company is holding negotiations on a purchase in Russia with several companies, but refused to clarify whether these companies are purely Russian or are subsidiaries of foreign pharmaceutical manufacturers.

Takeda was founded in 1781 and is headquartered in Osaka, Japan. The company owns 25 production enterprises in 18 countries. In 2013, the company celebrated 20 years of work in Russia. 

29 November 2015
Yaroslavl region

Investor profile

Takeda Pharmaceutical Company Limited


Company's website: https://www.takeda.com

T: +81-3-3278-3256

Public company

E-mail: jeffrey.cross@takeda.com

Contact: Christophe Weber, Representative Director

Takeda Pharmaceutical Company Limited (Takeda) is a research-based global company that primarily focuses on pharmaceuticals. Takeda has an active commercial presence in such therapeutic areas as central nervous system diseases, cardiovascular and metabolic diseases, gastroenterology, oncology and vaccines.  Takeda’s strong presence in North America, Japan and other Asian countries was further supplemented with good positions in Europe and rapidly growing emerging markets following its merger with Nycomed. The merged company is represented in more than 70 countries, ranks fifteenth among the biggest companies in the global pharmaceutical industry and has the world’s seventh largest portfolio of advanced developments.